TRPA1

2018

  • by

2018. 2020 Huang and Docampo. This content is definitely distributed under the terms of the Creative Commons Attribution 4.0 International license. DATA Collection?S1. (A) List… Read More »2018

b Macrophages were treated with different A2ti (25 or 50?M), an anti-A2 antibody (25?g/mL), or maraviroc (25?g/mL) prior to exposure to HIV-1JR-CSF (MOI?=?1)

  • by

b Macrophages were treated with different A2ti (25 or 50?M), an anti-A2 antibody (25?g/mL), or maraviroc (25?g/mL) prior to exposure to HIV-1JR-CSF (MOI?=?1). A2 and… Read More »b Macrophages were treated with different A2ti (25 or 50?M), an anti-A2 antibody (25?g/mL), or maraviroc (25?g/mL) prior to exposure to HIV-1JR-CSF (MOI?=?1)

* 0

  • by

* 0.05, ** 0.01. and NK cell tumor infiltration, expression of Th1 AC710 associated genes in the injection site, and increased frequency of splenic tumor-specific… Read More »* 0